ImmunityBio (IBRX) Enterprise Value (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Enterprise Value of -$380.0 million for Q1 2026, down 526.63% year-over-year from $89.1 million in Q1 2025, and down 57.07% quarter-over-quarter from -$241.9 million in Q4 2025.
ImmunityBio (IBRX) Enterprise Value (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Enterprise Value for 13 consecutive years, with -$380.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 526.63% year-over-year to -$380.0 million; the TTM figure through Mar 2026 stood at -$380.0 million (down 526.63% YoY), while the FY2025 annual figure was -$241.9 million, down 62.54% from the prior year.
- Enterprise Value declined to -$380.0 million in Q1 2026 per IBRX's latest filing, from -$241.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$49.0 million in Q2 2023 and bottomed at -$380.0 million in Q1 2026.
- Historically, Enterprise Value has averaged -$168.0 million across 5 years, with a median of -$152.7 million in 2025.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 65.6% — and 2026, when it sank 526.63%.
- ImmunityBio's Enterprise Value stood at -$109.7 million in 2022, then tumbled by 141.99% to -$265.4 million in 2023, then jumped by 43.92% to -$148.8 million in 2024, then plunged by 62.54% to -$241.9 million in 2025, then sank by 57.07% to -$380.0 million in 2026.
- Business Quant data shows IBRX's Enterprise Value at -$380.0 million in Q1 2026, -$241.9 million in Q4 2025, and -$256.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -356.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -356.50 Mn |
| Mar 31, 2026 | -380.00 Mn |
| Dec 31, 2025 | -241.92 Mn |
| Sep 30, 2025 | -256.90 Mn |
| Jun 30, 2025 | -152.73 Mn |
| Mar 31, 2025 | -60.64 Mn |
| Dec 31, 2024 | -148.84 Mn |
| Sep 30, 2024 | -129.38 Mn |
| Jun 30, 2024 | -216.97 Mn |
| Mar 31, 2024 | -169.47 Mn |
| Dec 31, 2023 | -265.41 Mn |
| Sep 30, 2023 | -188.72 Mn |
| Jun 30, 2023 | -49.02 Mn |
| Mar 31, 2023 | -94.00 Mn |
| Dec 31, 2022 | -109.68 Mn |
| Sep 30, 2022 | -113.44 Mn |
| Jun 30, 2022 | -85.10 Mn |
| Mar 31, 2022 | -194.24 Mn |
| Dec 31, 2021 | -318.86 Mn |
| Sep 30, 2021 | -81.82 Mn |